Popular Trials
Monoclonal Antibodies
Faricimab for Diabetic Macular Edema
Recruiting3 awardsPhase 4
Mesa, Arizona
This trial is designed to see if faricimab is an effective treatment for diabetic macular edema in underrepresented patients who have not yet received treatment. The study population will consist of participants who self-identify as Black/African American, Hispanic/Latino American, or Native American/Alaska Native/Native Hawaiian or other Pacific Islander.
Gene Therapy
RGX-314 Gene Therapy for Diabetic Retinopathy
Recruiting1 awardPhase 2
Phoenix, Arizona
This trial is testing a new gene therapy treatment for diabetic retinopathy, a progressive complication of diabetes that is a leading cause of vision loss. The new treatment is being developed as a potential one-time treatment that may provide a longer duration of therapeutic effect and intervene at an earlier stage of the disease.
Popular Filters
Trials for Diabetic Macular Edema Patients
Monoclonal Antibodies
Foselutoclax for Diabetic Macular Edema
Recruiting1 awardPhase 2
Bakersfield, California
This trial is testing foselutoclax, a new drug, in patients with Diabetic Macular Edema who haven't responded to other treatments. The drug works by blocking a protein to reduce eye swelling and improve vision.
Corticosteroid
ILUVIEN® Implant for Diabetic Macular Edema
Recruiting3 awardsPhase 4
Phoenix, Arizona
This trial is testing whether or not a new treatment for DME is better than the standard treatment. It will enroll patients who have not had any DME treatments for the past 12 months, and compare the new treatment to the standard treatment.
Monoclonal Antibodies
PDS with Ranibizumab vs. Intravitreal Ranibizumab for Diabetic Macular Edema
Recruiting2 awardsPhase 3
Mesa, Arizona
This trial will compare the effects of two different ways of delivering a drug to treat diabetic macular edema. One group will receive the drug every four weeks, and the other group will receive the drug every 24 weeks.
Trials for DME Patients
Monoclonal Antibodies
Foselutoclax for Diabetic Macular Edema
Recruiting1 awardPhase 2
Bakersfield, California
This trial is testing foselutoclax, a new drug, in patients with Diabetic Macular Edema who haven't responded to other treatments. The drug works by blocking a protein to reduce eye swelling and improve vision.
Corticosteroid
ILUVIEN® Implant for Diabetic Macular Edema
Recruiting3 awardsPhase 4
Phoenix, Arizona
This trial is testing whether or not a new treatment for DME is better than the standard treatment. It will enroll patients who have not had any DME treatments for the past 12 months, and compare the new treatment to the standard treatment.
Monoclonal Antibodies
PDS with Ranibizumab vs. Intravitreal Ranibizumab for Diabetic Macular Edema
Recruiting2 awardsPhase 3
Mesa, Arizona
This trial will compare the effects of two different ways of delivering a drug to treat diabetic macular edema. One group will receive the drug every four weeks, and the other group will receive the drug every 24 weeks.
Phase 3 Trials
Monoclonal Antibodies
PDS with Ranibizumab vs. Intravitreal Ranibizumab for Diabetic Macular Edema
Recruiting2 awardsPhase 3
Mesa, Arizona
This trial will compare the effects of two different ways of delivering a drug to treat diabetic macular edema. One group will receive the drug every four weeks, and the other group will receive the drug every 24 weeks.
Vamikibart for Uveitic Macular Edema
Recruiting1 awardPhase 3
Hagerstown, Maryland
This trial is testing vamikibart, a medication that may reduce eye swelling caused by inflammation. It focuses on people with uveitic macular edema, aiming to improve their condition by calming the inflammation in their eyes.
Anti-VEGF
Aflibercept for Age-Related Macular Degeneration and Diabetic Macular Edema
Recruiting2 awardsPhase 3
Waterford, Connecticut
This trial is testing a new drug called aflibercept 8 mg on people with nAMD and DME who have already used other medications. The goal is to see how safe and effective the drug
Trials With No Placebo
Monoclonal Antibodies
Foselutoclax for Diabetic Macular Edema
Recruiting1 awardPhase 2
Bakersfield, California
This trial is testing foselutoclax, a new drug, in patients with Diabetic Macular Edema who haven't responded to other treatments. The drug works by blocking a protein to reduce eye swelling and improve vision.
Corticosteroid
ILUVIEN® Implant for Diabetic Macular Edema
Recruiting3 awardsPhase 4
Phoenix, Arizona
This trial is testing whether or not a new treatment for DME is better than the standard treatment. It will enroll patients who have not had any DME treatments for the past 12 months, and compare the new treatment to the standard treatment.
Nonsteroidal Anti-inflammatory Drug
Episcleral Celecoxib for Macular Edema
Recruiting1 awardPhase 1
Palo Alto, California
This trial is testing a treatment called Episcleral Celecoxib, which is applied to the outer layer of the eye. It is aimed at patients with macular edema and other inflammatory eye conditions. The drug works by reducing swelling and preventing harmful blood vessel growth in the eye. The main goal is to see if the treatment is safe and if it can improve vision by reducing inflammation.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.